Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
May 29, 2025 16:15 ET | Source: Alumis Inc.

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis to present at Jefferies Global Healthcare Conference on June 4, 2025
May 29, 2025 07:55 ET | Source: Alumis Inc.

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
May 21, 2025 09:10 ET | Source: Alumis Inc.

Alumis Completes Merger with ACELYRIN

Alumis Completes Merger with ACELYRIN
May 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
May 13, 2025 13:00 ET | Source: Alumis Inc.

Alumis Stockholders Approve Merger with ACELYRIN

Alumis Stockholders Approve Merger with ACELYRIN
April 21, 2025 06:30 ET | Source: Alumis Inc.

Alumis and ACELYRIN Announce Amended Merger Agreement

Alumis and ACELYRIN Announce Amended Merger Agreement
April 04, 2025 16:34 ET | Source: Alumis Inc.; ACELYRIN, INC.

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and ACELYRIN file joint definitive proxy statement for proposed merger, expected to close in 2Q 2025
March 25, 2025 02:30 ET | Source: Alumis Inc.

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
March 19, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Next Page keyboard_arrow_right